Application of antisense oligonucleotide in the treatment of inherited retinal dystrophy

Authors: Li Wuyi,  Sui Ruifang
DOI: 10.3760/cma.j.cn115989-20210128-00074
Published 2022-01-10
Cite asChin J Exp Ophthalmol, 2022, 40(1): 67-72.

Abstract

Gene therapy is expected to restore the function of genetic material fundamentally and it has become a new trend in inherited retinal dystrophy treatment. Antisense oligonucleotide (AON) is a kind of small molecule nucleic acid drug, which can specifically bind to messenger RNA through the base pairing principle, thus interfering or modifying gene expression at the transcription and translation level.Possessing the advantages of high specificity and efficiency, wide targeting range, low immunogenicity and limited adverse effect, AON has become a novel remedy for inherited retinal dystrophy.Currently, three different AON drugs have already been used in clinical trials for inherited retinal dystrophy.In this review, the chemical structure modification, properties and mechanism of AON, and the therapeutic strategies of AON in different inherited retinal dystrophy diseases in recent years were summarized.

Key words:

Oligonucleotides, antisense; Genetic therapy; Retinal dystrophies, inherited

Contributor Information

Li Wuyi

Department of Ophthalmology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China

Sui Ruifang

Department of Ophthalmology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China

(Read 5 times, 1 visits today)